Discovery of an Orally Bioavailable KRAS G12D Inhibitor

Discovery of INCB159020, an Orally Bioavailable KRAS G12D Inhibitor.

GMTEYKLVVVGADGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFL
CVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQGVDDAFYTL
VREIRKHKEK

0.1 M Sodium acetate, pH 4.6,30% PEG 4000 and 0.2M ammonium acetate

Hydrogens have been added in their riding positions

Inhibitor, Oncoprotein, GTPase, HYDROLASE, HYDROLASE-HYDROLASE INHIBITOR complex

MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLC
VFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQGVDDAFYTLV
REIRKHKEK